Sanofi, Regeneron Setting 'New Paradigm' With Dupixent Pricing In US?
Executive Summary
Companies employed collaborative outreach with payers to arrive at 'responsible' price for atopic dermatitis biologic.
You may also be interested in...
JAK Inhibitor Safety Concerns vs Rebates: Which Will Impact Atopic Dermatitis Drug Access More?
ICER discussion on the health benefit of several upcoming drugs for atopic dermatitis, including several JAK inhibitors, touches on safety concerns and the likelihood that increased competition will open the door to higher list prices and rebating in the class.
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, a broader label than AstraZeneca's Fasenra, GSK's Nucala and Teva's Cinqair.
We Haven’t Ruled Out Drug Price Increases, Says Regeneron’s Schleifer
In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.